Artiva Biotherapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Artiva Biotherapeutics, Inc. (ARTV) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-65.37-28.72-58.79-71.83-17.99
Depreciation & Amortization2.432.271.160.250.07
Stock Based Compensation6.987.056.584.310.30
Change in Working Capital-0.33-28.28-3.8733.414.36
Change in Accounts Receivable1.03-0.51-0.06-0.470.00
Change in Accounts Payable0.52-0.410.19-1.241.82
Change in Other Working Capital-1.88-0.84-1.5518.552.54
Other Operating Activities3.600.710.0018.55-0.28
Net Cash from Operating Activities-55.03-47.43-50.83-15.30-13.54
Investing Activities
Capital Expenditures-0.64-3.26-6.30-1.72-0.28
Purchases of Investments-119.82-22.720.000.000.00
Sales/Maturities of Investments56.3526.800.000.000.00
Net Cash from Investing Activities-120.46-25.98-6.30-1.72-0.28
Financing Activities
Debt Repayment-0.150.000.000.000.00
Common Stock Issued166.560.010.330.180.22
Common Stock Repurchased-4.18-0.010.000.000.00
Other Financing Activities-4.1824.39-1.59-2.03-0.46
Net Cash from Financing Activities162.2324.39-1.26152.7537.40
Summary
Net Change in Cash-13.27-49.01-58.39135.7323.57
Cash at Beginning of Period53.76102.78161.1725.440.00
Cash at End of Period40.4953.76102.78161.170.00
Free Cash Flow-55.67-50.69-57.13-17.03-13.83
Supplemental Disclosures
Income Taxes Paid0.000.080.000.000.00